ES2149264T3 - Agente terapeutico para el tratamiento de melanomas. - Google Patents

Agente terapeutico para el tratamiento de melanomas.

Info

Publication number
ES2149264T3
ES2149264T3 ES94911013T ES94911013T ES2149264T3 ES 2149264 T3 ES2149264 T3 ES 2149264T3 ES 94911013 T ES94911013 T ES 94911013T ES 94911013 T ES94911013 T ES 94911013T ES 2149264 T3 ES2149264 T3 ES 2149264T3
Authority
ES
Spain
Prior art keywords
melanomas
treatment
therapeutic agent
component
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94911013T
Other languages
English (en)
Inventor
Lance Elliot Schlipalius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognis Australia Pty Ltd
Original Assignee
Cognis Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognis Australia Pty Ltd filed Critical Cognis Australia Pty Ltd
Application granted granted Critical
Publication of ES2149264T3 publication Critical patent/ES2149264T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTA UN AGENTE TERAPEUTICO PARA EL TRATAMIENTO DE UN MELANOMA O MELANOMAS MEDIANTE INYECCION O FORMA INTRAVENOSA QUE INCLUYE UNA MEZCLA DE: A) UN COMPONENTE DISPERSIBLE SOLUBLE EN AGUA; B) UN COMPONENTE EMULSIFICANTE Y C) UN COMPONENTE CAROTENOIDE INSOLUBLE EN AGUA EN UN MEDIO PORTADOR ADECUADO.
ES94911013T 1993-03-22 1994-03-22 Agente terapeutico para el tratamiento de melanomas. Expired - Lifetime ES2149264T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPL793493 1993-03-22

Publications (1)

Publication Number Publication Date
ES2149264T3 true ES2149264T3 (es) 2000-11-01

Family

ID=3776793

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94911013T Expired - Lifetime ES2149264T3 (es) 1993-03-22 1994-03-22 Agente terapeutico para el tratamiento de melanomas.

Country Status (10)

Country Link
US (2) US5705180A (es)
EP (1) EP0689426B1 (es)
JP (1) JPH08510994A (es)
AT (1) ATE192921T1 (es)
DE (1) DE69424537T2 (es)
DK (1) DK0689426T3 (es)
ES (1) ES2149264T3 (es)
GR (1) GR3034167T3 (es)
PT (1) PT689426E (es)
WO (1) WO1994021231A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM493194A0 (en) * 1994-04-08 1994-05-05 Buckmeier, Julie A. Therapeutic agent for inhibiting the conversion of epithelial cells to tumours
US6428816B1 (en) * 1994-04-08 2002-08-06 Cognis Australia Pty., Ltd. Carotenoid agent for inhibiting the conversion of epithelial cells to tumors
DE19609476A1 (de) * 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
WO1998045241A2 (en) 1997-04-04 1998-10-15 Henkel Corporation Lutein esters having high bioavailability
GB9718636D0 (en) * 1997-09-04 1997-11-05 Smithkline Beecham Plc Novel composition and use
US20070087993A1 (en) 1999-07-29 2007-04-19 Steven Baranowitz Method for transdifferentiation of body tissues
US7070796B1 (en) * 1999-08-30 2006-07-04 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation for parenteral administration
US6277417B1 (en) * 2000-04-07 2001-08-21 Triarco Industries, Inc. Method of inhibiting 5α-reductase with astaxanthin
WO2002047725A2 (fr) * 2000-12-12 2002-06-20 Debiopharm S.A. Preparation pharmaceutique d'oxaliplatine pour administration par voie parenterale et procede d'obtention de ladite preparation
US6635293B2 (en) * 2001-10-23 2003-10-21 Kemin Foods, L.C. Finely dispersed carotenoid suspensions for use in foods and a process for their preparation
US6759436B2 (en) 2002-02-01 2004-07-06 Micelle Products, Inc. Clear micellized formulations of β-carotene and method of treating leukoplakia
US6890961B2 (en) 2002-02-01 2005-05-10 Micelle Products, Inc. Clear micellized formulations of β-carotene and method of treating leukoplakia
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
EP2392562B1 (en) * 2002-07-29 2018-03-07 Cardax Pharma, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7074990B2 (en) * 2003-06-27 2006-07-11 Agricultural Research Organization, The Volcani Center Carotenoids rich paprika cultivars
JP4526244B2 (ja) 2003-06-30 2010-08-18 ブラザー工業株式会社 インクジェットヘッド及びインクジェットプリンタ並びにインクジェットヘッドの製造方法
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
US7351424B2 (en) * 2004-07-22 2008-04-01 Bio Lut S.A. De C.V. Enhanced purity trans-lutein-ester compositions and methods of making same
US20070065487A1 (en) * 2005-09-21 2007-03-22 Bio Lut S.A. De C.V. Trans-lutein xantophyll ester of high purity and high bioavailability in micellar solution and a process for the preparation thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4572915A (en) * 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
US4680314A (en) * 1985-08-30 1987-07-14 Microbio Resources, Inc. Process for producing a naturally-derived carotene/oil composition by direct extraction from algae
AU595824B2 (en) * 1985-08-30 1990-04-12 Betatene Limited Narurally-derived carotene/oil composition and the process for the production thereof by direct extraction of carotene from algae
WO1989006977A1 (en) * 1988-02-04 1989-08-10 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
JPH0225418A (ja) * 1988-07-14 1990-01-26 Kyorin Pharmaceut Co Ltd イブジラスト脂肪乳剤およびその製造方法
US5196198A (en) * 1989-06-02 1993-03-23 Abbott Laboratories Parenteral nutrition product
EP0400547A1 (en) * 1989-06-02 1990-12-05 Abbott Laboratories Parenteral nutrition product
GB8919172D0 (en) * 1989-08-23 1989-10-04 Univ Nottingham Useful composition
US5079016A (en) * 1990-05-16 1992-01-07 Kalamazoo Holdings, Inc. Color-stabilized carotenoid pigment compositions and foods colored therewith having increased resistance to oxidative color fading
AU660630B2 (en) * 1990-10-01 1995-07-06 Brigham And Women's Hospital Beta-carotene and vitamin E therapy for inhibition of major vascular events
DE4031094A1 (de) * 1990-10-02 1992-04-09 Basf Ag Verfahren zur herstellung von stabilen injizierbaren (beta)-carotin-solubilisaten
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
US5298246A (en) * 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
CH681152A5 (de) * 1991-06-04 1993-01-29 Marigen S.A. Neue biotenside und antitumorale ester und phosphatide mit vitamin-d- und vitamin-e-verbindungen, ihre herstellung und aufarbeitung zu spontan dispergierbaren konzentraten.
JP3302999B2 (ja) * 1991-09-06 2002-07-15 コグニス・オーストラリア・プロプライエタリ・リミテッド カロチノイド・コンポジション
EP0621773B1 (en) * 1992-01-16 1998-11-25 The Board Of Regents, The University Of Texas System Formulation and use of carotenoids in treatment of cancer
WO1993024454A1 (en) * 1992-06-04 1993-12-09 Betatene Limited High cis beta-carotene composition

Also Published As

Publication number Publication date
WO1994021231A1 (en) 1994-09-29
DK0689426T3 (da) 2000-10-30
ATE192921T1 (de) 2000-06-15
US5897871A (en) 1999-04-27
US5705180A (en) 1998-01-06
JPH08510994A (ja) 1996-11-19
PT689426E (pt) 2000-11-30
EP0689426B1 (en) 2000-05-17
DE69424537D1 (de) 2000-06-21
EP0689426A1 (en) 1996-01-03
DE69424537T2 (de) 2001-11-15
EP0689426A4 (en) 1998-07-29
GR3034167T3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
ES2149264T3 (es) Agente terapeutico para el tratamiento de melanomas.
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
NZ296893A (en) Treatment/prevention of adverse reactions to skin irritants by administration of a loop diuretic optionally in conjunction with a mast cell degranulator or a glucocorticosteroid;transdermal delivery device
GEP20053539B (en) Antidiabetic Formulation
ES2157958T3 (es) Uso de venlafaxina o de un compuesto de ariloxipropanamina para la preparacion de un medicamento para el tratamiento de la incontinencia urinaria.
ES2114931T3 (es) Nuevos esteres esteroidales.
AR015966A1 (es) Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
DK0770384T3 (da) Faste, vandfrie farmaceutiske sammensætninger til vaginal anvendelse
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ES2176702T3 (es) Antimicoticos con alta liberacion de sustancia activa.
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
PT986386E (pt) Uso de derivados heterociclicos aromaticos com azoto no tratamento topico de doencas dos tecidos epiteliais
PT1014951E (pt) Composicao de revestimento farmaceutica e metodo para a sua utilizacao
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
AR035986A1 (es) Uso de derivados anti-convulsivos para la manufactura de un medicamento util para el tratamiento del temblor esencial

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 689426

Country of ref document: ES